These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 33037191)

  • 41. Cell cycle inhibition therapy that targets stathmin in in vitro and in vivo models of breast cancer.
    Miceli C; Tejada A; Castaneda A; Mistry SJ
    Cancer Gene Ther; 2013 May; 20(5):298-307. PubMed ID: 23618950
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cisplatin-resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib.
    Wang L; Arras J; Katsha A; Hamdan S; Belkhiri A; Ecsedy J; El-Rifai W
    Mol Oncol; 2017 Aug; 11(8):981-995. PubMed ID: 28417568
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
    Dauch D; Rudalska R; Cossa G; Nault JC; Kang TW; Wuestefeld T; Hohmeyer A; Imbeaud S; Yevsa T; Hoenicke L; Pantsar T; Bozko P; Malek NP; Longerich T; Laufer S; Poso A; Zucman-Rossi J; Eilers M; Zender L
    Nat Med; 2016 Jul; 22(7):744-53. PubMed ID: 27213815
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Selective targeting of non-centrosomal AURKA functions through use of a targeted protein degradation tool.
    Wang R; Ascanelli C; Abdelbaki A; Fung A; Rasmusson T; Michaelides I; Roberts K; Lindon C
    Commun Biol; 2021 May; 4(1):640. PubMed ID: 34050235
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adenovirus-mediated Aurora A shRNA driven by stathmin promoter suppressed tumor growth and enhanced paclitaxel chemotherapy sensitivity in human breast carcinoma cells.
    Long M; Yin G; Liu L; Lin F; Wang X; Ren J; Wei J; Dong K; Zhang H
    Cancer Gene Ther; 2012 Apr; 19(4):271-81. PubMed ID: 22281755
    [TBL] [Abstract][Full Text] [Related]  

  • 46. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.
    Jones RA; Robinson TJ; Liu JC; Shrestha M; Voisin V; Ju Y; Chung PE; Pellecchia G; Fell VL; Bae S; Muthuswamy L; Datti A; Egan SE; Jiang Z; Leone G; Bader GD; Schimmer A; Zacksenhaus E
    J Clin Invest; 2016 Oct; 126(10):3739-3757. PubMed ID: 27571409
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MicroRNA-675 promotes glioma cell proliferation and motility by negatively regulating retinoblastoma 1.
    Zheng Y; Lu X; Xu L; Chen Z; Li Q; Yuan J
    Hum Pathol; 2017 Nov; 69():63-71. PubMed ID: 28970140
    [TBL] [Abstract][Full Text] [Related]  

  • 48. RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model.
    Byrne FL; Yang L; Phillips PA; Hansford LM; Fletcher JI; Ormandy CJ; McCarroll JA; Kavallaris M
    Oncogene; 2014 Feb; 33(7):882-90. PubMed ID: 23396365
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer.
    Alcaraz-Sanabria A; Nieto-Jiménez C; Corrales-Sánchez V; Serrano-Oviedo L; Andrés-Pretel F; Montero JC; Burgos M; Llopis J; Galán-Moya EM; Pandiella A; Ocaña A
    Mol Cancer Ther; 2017 Nov; 16(11):2552-2562. PubMed ID: 28847989
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alisertib inhibits migration and invasion of EGFR-TKI resistant cells by partially reversing the epithelial-mesenchymal transition.
    Wang CY; Lee MH; Kao YR; Hsiao SH; Hong SY; Wu CW
    Biochim Biophys Acta Mol Cell Res; 2021 May; 1868(6):119016. PubMed ID: 33744274
    [TBL] [Abstract][Full Text] [Related]  

  • 51. EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer.
    Beck TN; Georgopoulos R; Shagisultanova EI; Sarcu D; Handorf EA; Dubyk C; Lango MN; Ridge JA; Astsaturov I; Serebriiskii IG; Burtness BA; Mehra R; Golemis EA
    Mol Cancer Ther; 2016 Oct; 15(10):2486-2497. PubMed ID: 27507850
    [TBL] [Abstract][Full Text] [Related]  

  • 52. RB1: a prototype tumor suppressor and an enigma.
    Dyson NJ
    Genes Dev; 2016 Jul; 30(13):1492-502. PubMed ID: 27401552
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MiR-661 promotes tumor invasion and metastasis by directly inhibiting RB1 in non small cell lung cancer.
    Liu F; Cai Y; Rong X; Chen J; Zheng D; Chen L; Zhang J; Luo R; Zhao P; Ruan J
    Mol Cancer; 2017 Jul; 16(1):122. PubMed ID: 28716024
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer.
    Singer S; Malz M; Herpel E; Warth A; Bissinger M; Keith M; Muley T; Meister M; Hoffmann H; Penzel R; Gdynia G; Ehemann V; Schnabel PA; Kuner R; Huber P; Schirmacher P; Breuhahn K
    Cancer Res; 2009 Mar; 69(6):2234-43. PubMed ID: 19258502
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stathmin, interacting with Nf-κB, promotes tumor growth and predicts poor prognosis of pancreatic cancer.
    Lu Y; Liu C; Cheng H; Xu Y; Jiang J; Xu J; Long J; Liu L; Yu X
    Curr Mol Med; 2014 Mar; 14(3):328-39. PubMed ID: 24588766
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Translating RB1 predictive value in clinical cancer therapy: Are we there yet?
    Indovina P; Pentimalli F; Conti D; Giordano A
    Biochem Pharmacol; 2019 Aug; 166():323-334. PubMed ID: 31176618
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reversal of stathmin-mediated microtubule destabilization sensitizes retinoblastoma cells to a low dose of antimicrotubule agents: a novel synergistic therapeutic intervention.
    Mitra M; Kandalam M; Sundaram CS; Verma RS; Maheswari UK; Swaminathan S; Krishnakumar S
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5441-8. PubMed ID: 21546534
    [TBL] [Abstract][Full Text] [Related]  

  • 58. VHL loss predicts response to Aurora kinase A inhibitor in renal cell carcinoma cells.
    Ding XF; Zhou J; Chen G; Wu YL
    Mol Med Rep; 2018 Jul; 18(1):1206-1210. PubMed ID: 29845253
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells.
    Katsha A; Wang L; Arras J; Omar OM; Ecsedy J; Belkhiri A; El-Rifai W
    Clin Cancer Res; 2017 Jul; 23(14):3756-3768. PubMed ID: 28073841
    [No Abstract]   [Full Text] [Related]  

  • 60. Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration.
    Zheng X; Chi J; Zhi J; Zhang H; Yue D; Zhao J; Li D; Li Y; Gao M; Guo J
    Oncogene; 2018 Jan; 37(4):502-511. PubMed ID: 28967900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.